Fig. 3

HOXA10 overexpression promotes EOC cell proliferation and cisplatin resistance in vitro and in vivo. (a) HOXA10 mRNA is upregulated in cisplatin-resistant EOC cells and platinum-resistant EOC samples. (b) Results of the western-blot assays shows HOXA10 was up-regulated both in cisplatin-resistant EOC cells (upper) and platinum-resistant EOC samples (down). (c) Expression of HOXA10 protein in platinum-resistant (left) and platinum-sensitive (right) EOC tissues by IHC assay. (d and e) CCK8 and EdU proliferation assays confirm that HOXA10 overexpression promotes cell proliferation in EOC cells. (f) The chemosensitivity assay demonstrates higher IC50 of cisplatin in EOC cells with oe-HOXA10 transfection. (g) The IF assay shows that γH2AX foci is decreased in EOC cells with HOXA10 overexpression after cisplatin treatment (5 μM, 6 h). (h) The cell cycle assays show that HOXA10 overexpression can alleviate the blocking in the G2/M phase induced by cisplatin (5 μM 48 h). (i) The apoptosis assays show that HOXA10 overexpression can lower the percentage of cell apoptosis induced by cisplatin (5 μM, 48 h). (j) The animal study shows that HOXA10 overexpression promotes cell proliferation and resistance to cisplatin in vivo